IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, an oral, once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.